The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Selecting and sequencing therapies for R/R multiple myeloma
Sagar Lonial, MD, FACP, Emory University School of Medicine, Atlanta, GA, discusses the selection and sequencing of therapies for relapsed/refractory (R/R) multiple myeloma. He highlights that this depends on which prior treatment the patient is refractory to and notes the role of CAR-T therapy in earlier lines of treatment. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
